71 results
8-K
EX-99.1
ARCT
Arcturus Therapeutics Holdings Inc
14 Nov 23
Arcturus Therapeutics Announces Third Quarter 2023 Financial Update
4:10pm
participant receiving two administrations of ARCT-032.
In September 2023, the CF Foundation agreed to increase its financial commitment to $25 million … , the timing for completion of the Phase 3 bivalent COVID vaccine trial, the Company’s continued commitment to ARCT-810, the timing of the final database
8-K
ARCT
Arcturus Therapeutics Holdings Inc
14 Nov 23
Arcturus Therapeutics Announces Third Quarter 2023 Financial Update
4:10pm
commitment to ARCT-810, the timing of the final database lock for the ARCT-810 Phase 1b study, the completion of enrollment of, and timing for interim data
8-K
EX-99.1
g18v3rvk fho
26 Sep 23
Entry into a Material Definitive Agreement
4:06pm
8-K
9ovloxrjvcejbx12 nya
21 Apr 23
Entry into a Material Definitive Agreement
5:21pm
8-K
EX-99.1
693azann5ery6
1 Sep 22
Arcturus Announces $63.2 Million Award from the U.S. Government to Support Development of
5:09pm
8-K
EX-99.1
46fm333
9 Aug 22
Arcturus Therapeutics Announces Second Quarter 2022 Financial Update and Pipeline Progress
12:00am
S-8
EX-4.3
fn2h12xv932eoo0kc0dr
30 Jun 22
Registration of securities for employees
4:05pm
8-K
EX-10.1
pemi sz6sfc
24 Jun 22
Entry into a Material Definitive Agreement
5:23pm
DEFR14A
0bugemjn9d jh
12 May 22
Revised proxy
5:00pm